APPA AP Pharma Inc. featured news, full reports, and detailed charts
AP Pharma Inc. (APPA) Wrap Up:
A.P. Pharma, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products using its proprietary polymer-based drug delivery technology. The company’s products include APF530, which is in Phase III clinical trial and is used for the prevention of acute onset and delayed onset chemotherapy-induced nausea and vomiting; and APF112, a Phase II clinical trial product that incorporates the mepivacaine, an anesthetic to provide post-surgical pain relief. Its preclinical products include APF328, a novel formulation for the treatment of pain following orthopedic surgery; APF505, which is a Biochronomer formulation that has the potential to deliv...AP Pharma Inc. (APPA*(D):NASDAQ)
Snapshot of AP Pharma Inc. (APPA)
|
OPEN
$0.92
|
PREVIOUS CLOSE
$0.91
|
|
|
DAY HIGH
$0.94
|
DAY LOW
$0.91
|
|
|
52 WEEK HIGH
05/26/09 - $1.21
|
52 WEEK LOW
12/18/08 - $0.30
|
|
|
MARKET CAP
36.0M
|
AVERAGE VOLUME 3 mo
61.8K
|
|
|
DILUTED EPS TTM
$-0.39
|
SHARES OUTSTANDING
39.4M
|
|
|
APPA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
APPA Top Compensated Officers
Executives, Board Directors
Key developments for AP Pharma Inc. (APPA)
AP Pharma Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net loss was $1.2 million or $0.04 basic and diluted net loss per share compared with a $6.2 million net loss or $0.20 basic and diluted net loss per share for the third quarter of 2008. The decreased net loss for the third quarter of 2009, as compared to the same period in 2008, was primarily due to lower research and development expenses related to APF530, largely reflecting the completion of the Phase 3 clinical trial, and recognition of income previously deferred, in connection with the termination of a license agreement for APF530 with RHEI Pharmaceuticals, N.V. (RHEI). Operating loss was $1.2 million against $6.3 million for the same quarter a year ago period. Loss from continuing operations was $1.2 million or $0.04 basic and diluted loss per share on contract revenues of 1.1 million against loss from continuing operations of 6.2 million or $0.20 basic and diluted loss per share on contract revenues of $64,000 for the same quarter a year ago period. For the nine-month period, the company reported net loss was $8.1 million or $0.26 basic and diluted net loss per share on contract revenues of $1.1 million against net loss of $19.2 million or $0.62 basic and diluted net loss per share on contract revenues of $348,000 for the same period a year ago. Loss from continuing operations was $8.1 million or $0.26 basic and diluted loss per share against $19.1 million or $0.62 basic and diluted loss per share for the same period a year ago. Operating loss was $8.1 million against $19.6 million for the same period a year ago.
AP Pharma Inc. expected to Report Fiscal Year 2009 Results on March 31, 2010. This event was calculated by Capital IQ (Created on November 16, 2009).
AP Pharma Inc. expected to Report Q3 2009 Results on November 10, 2009. This event was calculated by Capital IQ (Created on November 2, 2009).
APPA Competitors
| Company | Last | Change | |
| No competitor information is available for APPA. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | APPA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 265.2x |
|
| Price/Book | 20.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 301.2x |
|
|
APPA |
||
APPA transactions
| Type Date |
Target |
|
Private Placement
October 19, 2009 |
-- |